Market News & Trends
Third Rock Ventures Launches Cancer Immunotherapeutics Company With $47 Million
Third Rock Ventures, LLC recently announced the formation of Jounce Therapeutics, Inc. with a $47 million Series A financing of the company. Jounce is…
2/20/2013
Argos Therapeutics Announces Updated Phase II Data Argos Therapeutics Inc. recently announced updated results from its Phase II study of AGS-003, its most advanced product…
93% Shares of OctoPlus Acquired
Dr Reddy's Laboratories (DRL), which is in the process of acquiring Netherlands-based speciality pharmaceutical company OctoPlus NV for about 27.4 million euro, has so…
Argos Therapeutics Announces Updated Phase II Data
Argos Therapeutics Inc. recently announced updated results from its Phase II study of AGS-003, its most advanced product candidate for the treatment of metastatic…
2/13/2013
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders The range of potential therapeutic approaches available to treat…
Frost & Sullivan Sees Urgent Need for Cancer Diagnostics Tests; Finds Unmet Need for Key Disorders
The range of potential therapeutic approaches available to treat cancer is expected to expand rapidly during the next decade. Current diagnostic technologies focus on…
Lycera Expands Partnership With Merck; Potential $600-Million Deal
Lycera Corp. recently announced a collaboration agreement with Merck to discover, develop, and commercialize small-molecule therapies directed to selected novel targets being investigated for…
Novozymes Biopharma Announces Agreement With EpiVax
Novozymes Biopharma recently announced a collaborative research agreement with Rhode Island-based biotech company, EpiVax, Inc. to help further the development of a potential paradigm-shifting…
Perrigo Buys Company for $283 Million
Perrigo Company recently announced it has signed a definitive merger agreement and has completed the acquisition of Leeds, U.K.-based Rosemont Pharmaceuticals Ltd. for approximately…
Second Expansion Underway for Rexam Healthcare
Four years after its first extension, Rexam is again expanding its La Verpillière site (near Lyon) to create a building including approx. 2400 m2…
Xenon Receives Major Milestone for Marketing Approval
Xenon recently announced it has received a milestone payment from uniQure BV for the European Commission marketing approval of Glybera, a novel gene therapy…
Patheon Makes Investment to Expand Early Development Capabilities
Patheon Inc. recently announced plans for additional investment in its Milton Park facility. Located in Oxfordshire, UK, Milton Park is a dedicated pharmaceutical development…
Tapemark Expands Transdermal Patch Capabilities
Tapemark recently announced the addition of several new capabilities for transdermal patches, including the formulation, blending, and coating steps in the patch manufacturing process.…
2/6/2013
Foresite Capital Closes $100 Million Fund for Late-Stage Biotechs Biotech venture capital isn't what it used to be, but there's still money to invest in…
Bend Research Receives EU Certificate
Bend Research Inc. recently announced it has received certification of compliance with European Union (EU) Good Manufacturing Practice (GMP) regulations. This broad certification, which…
CROs Offer Promise of Innovative, Safe & Effective Development
Pharmaceutical and biotech companies are outsourcing research in order to develop innovative products that meet the rising demand for therapeutics across a range of…
Foresite Capital Closes $100 Million Fund for Late-Stage Biotechs
Biotech venture capital isn't what it used to be, but there's still money to invest in healthcare. Now one biotech investment firm just starting…
Generic Statins to Slash Global Market Value
The introduction of generic statins has kick-started a decline that will see the global statins market lose more than $7 billion in revenue by 2018,…
1/30/2013
Baxter International Makes $700-Million Acquisition Inspiration Biopharmaceuticals and Ipsen recently announced the sale of its lead hemophilia program, OBI-1 (recombinant porcine factor VIII), to Baxter…
Baxter International Makes $700-Million Acquisition
Inspiration Biopharmaceuticals and Ipsen recently announced the sale of its lead hemophilia program, OBI-1 (recombinant porcine factor VIII), to Baxter International. Baxter will acquire worldwide…
